What's new?The use of beta-blockers prior to out-of-hospital cardiac (OHCA) arrest may influence the first-registered heart rhythm.The different classes of beta-blockers have different effects on the first-registered heart rhythm in OHCA.The use of non-selective beta-blockers is associated with non-shockable heart rhythm in OHCA, particularly with pulseless electrical activity.The use of β1-selective beta-blockers is not associated with non-shockable heart rhythm in OHCA.When we considered differences in baseline comorbidities, the use of non-selective beta-blockers persisted associated with non-shockable heart rhythm.

Introduction
============

The incidence of shockable rhythm \[ventricular tachycardia (VT), ventricular fibrillation (VF)\] as first-registered heart rhythm in out-of-hospital cardiac arrest (OHCA) has exhibited an absolute and relative decline worldwide compared with non-shockable rhythm \[pulseless electrical activity (PEA) and asystole\] during the last decades.[@euaa124-B1] Several causes for this decreased incidence have been suggested, such as decline in mortality from ischaemic heart disease (IHD), increased use of implantable cardiac defibrillators, and improvements in heart failure management,[@euaa124-B1] with beta-blockers as cornerstone of the medical therapy.[@euaa124-B4] The chronic use of beta-blockers has increased significantly during the last decades primarily because of their favourable effects on mortality after myocardial infarction and in congestive heart failure (CHF).[@euaa124-B5] This increase has been suggested as one of the contributing factors for the decline of shockable rhythm in OHCA, considering the antifibrillatory and anti-arrhythmic properties of these drugs.[@euaa124-B2] Previous studies have shown that beta-blocker use may influence first-registered heart rhythm, but these studies have yielded conflicting results.[@euaa124-B6] Given the importance of the first-registered heart rhythm in post-resuscitation treatment and prognosis,[@euaa124-B10] we aimed to clarify this controversy by analysing real-world data from two large independent population-based OHCA-registries from Denmark and the Netherlands. We studied whether use of beta-blockers at the time of OHCA influenced the first-registered heart rhythm in OHCA (shockable vs. non-shockable). We distinguished between use of non-selective beta-blockers, β1-selective beta-blockers, and α-β-dual-receptor blockers, because these drug classes impact differently on various relevant cardiac and extracardiac functional properties.

Methods
=======

Data availability
-----------------

The data and study materials are not available to other researchers for purposes of reproducing the results or replicating the procedure.

Study design and setting
------------------------

We performed a population-based cohort study using data from two large ongoing Emergency Medical Services (EMS) attended OHCA-registries in Denmark and the Netherlands. Both registries are part of the ESCAPE-NET project that aims to study the causes and to develop effective treatments for OHCA across 10 European countries.[@euaa124-B11] From both cohorts, we included adult patients with OHCA of presumed cardiac cause (*Figure [1](#euaa124-F1){ref-type="fig"}*). We excluded patients with (i) unknown first-registered heart rhythm, (ii) presumed non-cardiac cause of OHCA (e.g. drowning, trauma, asphyxia), (iii) missing estimated time interval from recognition of OHCA to rhythm analysis by EMS, (iv) estimated time of arrival by EMS ≥30 min, or (v) incomplete drug dispensing records (this last condition only applied to the Dutch registry). This study was conducted according to the principles described in the Declaration of Helsinki and was approved by the Ethical Committee of the Academic Medical Center, Amsterdam, and the Danish Data Protection Agency (2007-58-0015, internal reference GEH-2014-017, I-Suite No. 02,735). In Denmark, ethical approval is not required for observational, registry-based studies where patients remain anonymous.

![Patient flow chart. (*A*) DANCAR registry. (*B*) ARREST registry. OHCA, out-of-hospital cardiac arrest.](euaa124f1){#euaa124-F1}

### Denmark

The population-based Danish Cardiac Arrest Register (DANCAR) includes all OHCAs across Denmark for which EMS were dispatched and where resuscitation efforts, either by a bystander or EMS personnel, have been attempted (2001--2014). The EMS is activated for all medical emergencies in Denmark, and EMS-personnel is required to fill out a case report form for every OHCA: the first-registered heart rhythm is reported in such case reports as a binary variable (non-shockable or shockable rhythm). The causes of OHCA were extrapolated from the death certificates and discharge diagnoses from the index hospitalization. When the cause of the underlying OHCA was cardiac disease, unknown disease, or unexpected collapse, the arrest was classified as of presumed cardiac cause. DANCAR has been described in detail elsewhere.[@euaa124-B12] All residents in Denmark have a unique and permanent personal civil registration number that allows individual-level linkage across nationwide registries. All admissions to Danish hospitals are registered since 1978 in the Danish National Patient Registry: diagnoses are classified according to the *International Classification of Diseases* (ICD). The National Prescription Register contains information on all dispensed drug prescriptions since 1995, classified according to the Anatomical Therapeutic Chemical (ATC) system. The Danish Civil Registration System provides data about patient's age and gender; the Danish Register of Causes of Death holds information about vital status and causes of death, including primary and contributing causes.

### The Netherlands

The population-based AmsteRdam REsuscitation STudies (ARREST) registry is an ongoing observational study that prospectively includes all OHCAs in one contiguous region of the Netherlands (North Holland province). This study region has a population of ∼2.6 million and covers 2404 km^2^, both rural and urban areas. A detailed description of ARREST is provided elsewhere.[@euaa124-B13] In short, the ARREST study centre is notified by the dispatch centre when there is a suspected OHCA in which EMS is involved. Electrocardiograms from EMS manual defibrillator or automated external defibrillation, whichever defibrillated first, were obtained to establish the first-registered heart rhythm. The first-registered heart rhythm was categorized as shockable (VT, VF) or non-shockable (asystole, PEA). For this study, data from 2009 to 2012 was used. To establish medication use, drug dispensing records 1 year prior to OHCA were obtained by contacting the patient's community pharmacy. These records were considered complete, since nearly all patients in the Netherlands are registered at a single community pharmacy. Medical history was obtained by contacting the hospital of admission and the general practitioner (GP). The GPs were asked to fill out a questionnaire to identify whether patients were diagnosed with any medical condition before their OHCA. Also, GP records contain information on hospital admissions and related diagnoses.[@euaa124-B13]

Exposure of interest
--------------------

Beta-blocker use was defined as starting in (ARREST) or covering (DANCAR) a period of maximum 90 days prior to OHCA (see [Supplementary material online, *Table S1*](https://academic.oup.com/europace/article-lookup/doi/10.1093/europace/euaa124#supplementary-data) for ATC codes). In DANCAR, the treatment duration was calculated by dividing the number of tablets from the prescription of interest by daily dosage. We determined the daily dosage estimating the mean dosage from up to five consecutive prescriptions before the prescription of interest.[@euaa124-B14] If more than one beta-blocker was prescribed within 90 days prior to OHCA, beta-blocker use was defined according to the most recent prescription. Moreover, in DANCAR, we stratified analyses according to the daily dosage (low/high) of beta-blockers (see [Supplementary material online, *Table S1*](https://academic.oup.com/europace/article-lookup/doi/10.1093/europace/euaa124#supplementary-data) for the classification of doses).

Similarly, we examined the association between angiotensin-converting enzyme (ACE) inhibitors, which have similar indications as beta-blockers, and first-registered heart rhythm to assess possible confounding by indication (see [Supplementary material online, *Table S2*](https://academic.oup.com/europace/article-lookup/doi/10.1093/europace/euaa124#supplementary-data) for ATC codes).

Covariates
----------

We identified baseline comorbidity up to 10 years before OHCA from the Danish National Patient Register (complete ICD codes are provided in [Supplementary material online, *Table S3*](https://academic.oup.com/europace/article-lookup/doi/10.1093/europace/euaa124#supplementary-data)). In ARREST, the same comorbidities were identified by contacting the hospital of admission and the GP. Also, use of medications with potential effects on first-registered heart rhythm was evaluated.[@euaa124-B9] Use of these medications were defined as having a drug dispensing record up to 180 days prior to OHCA. (ATC-codes are provided in [Supplementary material online, *Table S4*](https://academic.oup.com/europace/article-lookup/doi/10.1093/europace/euaa124#supplementary-data)).

Statistical analysis
--------------------

In both cohorts, the association between beta-blocker use and first-registered heart rhythm was studied using logistic regression analysis. Furthermore, in ARREST, we studied the association between beta-blocker use and specific first-registered heart rhythm---distinguishing between PEA and asystole---by multinomial logistic regression analysis using complete cases. We calculated both crude estimates (unadjusted analysis) and multivariable analysis adjusted for age, sex, OHCA-related parameters \[location of OHCA, presence/absence of bystander cardiopulmonary resuscitation (CPR) or EMS-witnessed OHCA, and time from recognition of OHCA to EMS arrival\], year of OHCA (only in DANCAR, because in ARREST we could only include OHCAs from 2009 to 2012) and all comorbidities and medications listed in *Table [1](#euaa124-T1){ref-type="table"}*. Analyses were conducted for the overall use of any beta-blocker (reference: no use of any beta-blocker), and separately for different classes of beta-blockers (reference: no use of any beta-blocker). Subgroup analysis was performed (i) among witnessed OHCAs (bystander or EMS witnessed) with estimated time to rhythm analysis ≤10 min and (ii) in subsets of patients classified by the presence of certain comorbidities at baseline: CHF, IHD, atrial fibrillation (AF), hypertension, and individuals without cardiovascular disease (absence of IHD, CHF, AF, or use of digoxin or antiarrhythmic drugs). Finally, we examined the association between ACE inhibitors and first-registered heart rhythm. Results are presented as odds ratios (ORs) with 95% confidence intervals (CIs). Categorical data are presented as absolute numbers and percentages, and continuous data as mean and standard deviation or medians together with their associated quartiles.

###### 

Baseline characteristics of subjects with out-of-hospital cardiac arrest stratified into beta-blocker users and non-users

                                                                                                       DANCAR            ARREST                                                        
  ---------------------------------------------------------------------------------------------------- ------------- --------------- ------------- ----------------- ----------------- ----------
  Total                                                                                                7022 (29.5)    16 812 (70.5)                   519 (32.8)        1065 (67.2)    
  Age (years), mean (SD)                                                                               72.7 (11.7)     69.2 (14.2)        NA         72.43 (10.9)      66.17 (14.4)        NA
  Male sex                                                                                             4845 (69.0)    11 447 (68.1)       NA          371 (71.5)        773 (72.6)         NA
  Resuscitation factors                                                                                                                                                                
   OHCA in private home                                                                                4644 (74.2)    10 161 (69.3)   2920 (12.2)     403 (77.6)        773 (72.7)      2 (0.1)
   Witnessed status                                                                                    3586 (51.2)     8550 (51.1)                                                     
    Bystander-witnessed OHCA                                                                           1012 (14.5)     2389 (14.3)     106 (0.5)      337 (65.7)        704 (66.5)      12 (0.8)
    EMS-witnessed OHCA                                                                                 2397 (34.3)     5794 (34.6)                     56 (10.9)         98 (9.3)      
    Unwitnessed OHCA                                                                                                                                  120 (23.4)        257 (24.3)     
   CPR status                                                                                                                                                                          
    Bystander CPR                                                                                      2645 (37.7)     6328 (37.7)     57 (0.2)       332 (65.0)        722 (68.7)      22 (1.4)
   EMS-witnessed OHCA                                                                                  1012 (14.4)     2389 (14.3)                     56 (10.9)         98 (9.3)      
   Neither bystander CPR nor EMS-witnessed OHCA                                                        3352 (47.9)     8051 (48.0)                    123 (24.1)        231 (22.0)     
   Median time from recognition of OHCA to EMS arrival, min (IQR)[^a^](#tblfn4){ref-type="table-fn"}   9 (4--15)        9 (4--14)         NA        8.2 (5.7--11.2)   8.1 (5.8--11.1)      NA
  Comorbidity                                                                                                                                                                          
   Ischaemic heart disease[^b^](#tblfn5){ref-type="table-fn"}                                          3704 (52.8)     2810 (16.7)        NA          219 (43.0)        165 (16.2)      55 (3.5)
   Congestive heart failure                                                                            2706 (38.5)     2059 (12.3)        NA          195 (38.7)        129 (12.7)      67 (4.2)
   Atrial fibrillation                                                                                 2211 (31.5)     1830 (10.9)        NA          147 (29.3)        123 (12.2)      70 (4.4)
   Chronic obstructive pulmonary disease                                                               1072 (15.3)     2286 (13.6)        NA           83 (16.7)        147 (14.6)      77 (4.9)
   Diabetes mellitus                                                                                   1783 (25.4)     2359 (14.0)        NA          167 (32.7)        173 (16.7)      51 (3.2)
   Cerebrovascular disease                                                                             1239 (17.6)     2004 (11.9)        NA           94 (18.8)        115 (11.4)      78 (4.9)
   Hypertension                                                                                        2155 (30.7)     2363 (14.1)        NA          334 (65.5)        421 (41.3)      55 (3.5)
   Dyslipidaemia                                                                                       3354 (47.8)     3093 (18.4)        NA          217 (42.7)        275 (27.0)      58 (3.7)
   Chronic kidney disease                                                                              802 (11.4)       684 (4.1)         NA           98 (19.8)         71 (7.1)       89 (5.6)
   Liver disease                                                                                       131 (1.9)        353 (2.1)         NA           19 (3.8)          30 (3.0)       89 (5.6)
  Concomitant medication                                                                                                                                                               
   Antipsychotics                                                                                      394 (5.6)       1334 (7.9)         NA           14 (2.7)          32 (3.0)          NA
   Antidepressants                                                                                     1356 (19.3)     2873 (17.1)        NA           33 (6.4)          64 (6.0)          NA
   Anxiolytics/hypnotics                                                                               1831 (26.1)     3550 (21.1)        NA          102 (19.7)        134 (12.6)         NA
   Corticosteroids                                                                                     759 (10.8)      1753 (10.4)        NA           35 (6.7)          73 (6.9)          NA
   Digoxin                                                                                             1411 (20.1)     1571 (9.4)         NA           59 (11.4)         36 (3.4)          NA
   Antiarrhythmic drugs, Class I and III                                                               287 (4.1)        184 (1.1)         NA           27 (5.2)          18 (1.7)          NA

Numbers are number (%) unless indicated otherwise.

*Note*: In the calculation of percentages, observations with missing value for the covariate involved in calculation were excluded.

CPR, cardiopulmonary resuscitation; EMS, emergency medical system; IQR, interquartile range; NA, not applicable; OHCA; out-of-hospital cardiac arrest; SD, standard deviation.

EMS-witnessed excluded.

Acute myocardial infarction included.

Results
=======

Patient characteristics
-----------------------

From DANCAR, we included 23 834 OHCA-patients (mean age 70.3, 68.4% male, *Figure [1](#euaa124-F1){ref-type="fig"}*). Of these, 7022 (29.5%) used a beta-blocker within 90 days before OHCA (*Table [1](#euaa124-T1){ref-type="table"}*), including 458 who used non-selective beta-blockers, 5432 who used β1-selective beta-blockers, and 1132 who used α-β-dual-receptor blockers (*Table [2](#euaa124-T2){ref-type="table"}*). From ARREST, we included 1584 OHCA-patients (mean age 68.2, 72.2% male, *Figure [1](#euaa124-F1){ref-type="fig"}*). Of these, 519 (32.8%) used a beta-blocker within 90 days before OHCA (*Table [1](#euaa124-T1){ref-type="table"}*), including 43 who used non-selective beta-blockers, 439 who used β1-selective beta-blockers, and 37 who used α-β-dual-receptor blockers (*Table [2](#euaa124-T2){ref-type="table"}*).

###### 

Baseline characteristics of subjects with out-of-hospital cardiac arrest divided into users of non-selective beta-blockers, β1-selective beta-blockers, and α-β-dual-receptor blockers

                                                                                                           DANCAR        ARREST                                                                                      
  ----------------------------------------------------------------------------------------------------- ------------- ------------- ------------- ------------ ----------------- ----------------- ----------------- ----------
  Total                                                                                                   458 (6.5)    5432 (77.4)   1132 (16.1)                   43 (8.3)         439 (84.6)         37 (7.1)      
  Age (years), mean (SD)                                                                                 72.3 (11.9)   73.2 (11.6)   70.6 (11.7)       NA        73.32 (12.7)      72.69 (10.6)      68.33 (12.0)        NA
  Male sex                                                                                               271 (59.2)    3707 (68.2)   867 (76.6)        NA          30 (69.8)        318 (72.4)         23 (62.2)         NA
  Resuscitation factors                                                                                                                                                                                              
   OHCA in private home, *n* (%)                                                                         309 (78.4)    3547 (73.5)   788 (75.7)    765 (10.9)      37 (86.0)        332 (75.6)         34 (91.9)         NA
   Witnessed status                                                                                      210 (46.1)    2783 (51.4)                                                                                   
    Bystander-witnessed OHCA                                                                              68 (14.9)    801 (14.8)    593 (52.6)     27 (0.4)       27 (65.9)        288 (66.1)         22 (61.1)      6 (1.2)
    EMS-witnessed OHCA                                                                                   178 (39.0)    1827 (33.8)   143 (12.7)                    8 (19.5)          41 (9.4)          7 (19.4)      
    Unwitnessed OHCA                                                                                                                 392 (34.7)                    6 (14.6)         107 (24.5)         7 (19.4)      
   CPR status                                                                                                                                                                                                        
    Bystander CPR                                                                                        149 (32.6)    2056 (37.9)   440 (38.9)     13 (0.2)       24 (60.0)        288 (66.2)         20 (55.6)      8 (1.5)
    EMS-witnessed OHCA                                                                                    68 (14.7)    801 (14.8)    143 (12.6)                    8 (20.0)          41 (9.4)          7 (19.4)      
    Neither bystander CPR nor EMS-witnessed OHCA                                                         241 (52.7)    2563 (47.3)   548 (48.5)                    8 (20.0)         106 (24.4)         7 (19.4)      
   Median time from recognition of OHCA to EMS arrival, min (IQR)[^b^](#tblfn10){ref-type="table-fn"}     9 (3--15)     9 (4--15)    10 (4--15)        NA       9.4 (4.6--13.0)   8.2 (5.9--11.2)   7.3 (4.0--10.1)      NA
  Comorbidity                                                                                                                                                                                                        
   Ischaemic heart disease[^c^](#tblfn11){ref-type="table-fn"}                                           132 (28.8)    2855 (52.6)   717 (63.3)        NA          21 (48.8)        178 (41.4)         20 (55.6)      10 (1.9)
   Congestive heart failure                                                                               75 (16.4)    1777 (32.7)   854 (75.4)        NA          14 (34.1)        155 (36.4)         26 (70.3)      15 (2.9)
   Atrial fibrillation                                                                                   125 (27.3)    1718 (36.6)   368 (32.5)        NA          14 (34.1)        122 (28.7)         11 (30.6)      17 (3.3)
   Chronic obstructive pulmonary disease                                                                  66 (14.4)    817 (15.0)    189 (16.7)        NA          12 (28.6)         63 (14.9)         8 (23.5)       21 (4.0)
   Diabetes mellitus                                                                                      97 (21.2)    1339 (24.7)   347 (30.7)        NA          13 (31.0)        137 (31.7)         17 (47.2)      9 (1.7)
   Cerebrovascular disease                                                                                68 (14.9)    973 (17.9)    198 (17.5)        NA          11 (26.2)         75 (17.7)         8 (23.5)       19 (3.7)
   Hypertension                                                                                          109 (23.8)    1655 (30.5)   391 (34.5)        NA          22 (51.2)        286 (66.2)         26 (74.3)      9 (1.7)
   Dyslipidaemia                                                                                         100 (21.8)    2608 (48.0)   646 (57.1)        NA          21 (48.8)        180 (41.9)         16 (45.7)      11 (2.1)
   Chronic kidney disease                                                                                 21 (4.6)     583 (10.7)    198 (17.5)        NA          9 (22.0)          78 (18.6)         11 (32.4)      25 (4.8)
   Liver disease                                                                                          25 (5.5)      77 (1.4)      29 (2.6)         NA           4 (9.8)          12 (2.9)           3 (8.8)       24 (4.6)
  Concomitant medication                                                                                                                                                                                             
   Antipsychotics                                                                                         48 (10.5)     293 (5.4)     53 (4.7)         NA              0             14 (3.2)              0             NA
   Antidepressants                                                                                       124 (27.1)    1016 (18.7)   216 (19.1)        NA           4 (9.3)          24 (5.5)          5 (13.5)          NA
   Anxiolytics/hypnotics                                                                                 151 (33.0)    1369 (25.2)   311 (27.5)        NA          9 (20.9)          81 (18.5)         12 (32.4)         NA
   Corticosteroids                                                                                        50 (10.9)    585 (10.8)    124 (11.0)        NA           4 (9.3)          30 (6.8)           1 (2.7)          NA
   Digoxin                                                                                                70 (15.3)    1055 (19.4)   286 (25.3)        NA           3 (7.0)          49 (11.2)         7 (18.9)          NA
   Antiarrhythmic drugs, Class I and III                                                                   9 (2.0)      188 (3.5)     89 (7.9)         NA           3 (7.0)          19 (4.3)          5 (13.5)          NA

Numbers are number (%) unless indicated otherwise.

*Note*: In the calculation of percentages, observations with missing value for the covariate involved in calculation were excluded.

CPR, cardiopulmonary resuscitation; EMS, emergency medical system; IQR, interquartile range; NA, not applicable; OHCA; out-of-hospital cardiac arrest; SD, standard deviation.

Percentage of the total number of patients using beta-blockers.

EMS-witnessed excluded.

Acute myocardial infarction included.

Beta-blocker use and first-registered heart rhythm
--------------------------------------------------

In DANCAR, the overall use of beta-blockers was associated with increased odds of non-shockable rhythm \[OR~adj~ 1.16 (1.07--1.26), *Figure [2](#euaa124-F2){ref-type="fig"}*\] compared with no use of any beta-blocker. We found a significant association between non-shockable rhythm and use of non-selective beta-blockers \[OR~adj~ 1.93 (1.48--2.52)\] or α-β-dual-receptor blockers \[OR~adj~ 1.21 (1.03--1.42)\], but not β1-selective beta-blockers \[OR~adj~ 1.04 (0.95--1.13)\]. In ARREST, the overall use of beta-blockers was not associated with increased odds of non-shockable rhythm \[OR~adj~ 1.08 (0.82--1.42), *Figure [2](#euaa124-F2){ref-type="fig"}*\]. The other key findings in DANCAR were reproduced in ARREST: increased odds of non-shockable rhythm was associated with use of non-selective beta-blockers \[OR~adj~ 2.52 (1.15--5.49)\], but not β1-selective beta-blockers \[OR~adj~ 0.99 (0.74--1.31)\]. Use of α-β-dual-receptor blockers was not significantly associated with non-shockable rhythm \[OR~adj~ 1.37 (0.61--3.07), *Figure [2](#euaa124-F2){ref-type="fig"}*\]. We also found that non-selective beta-blocker use was associated with PEA \[OR~adj~ 2.38 (1.01--5.65)\], but not asystole \[OR~adj~ 2.34 (0.89--6.18)\] when compared with shockable rhythm (*Figure [3](#euaa124-F3){ref-type="fig"}*). Neither use of β1-selective beta-blockers nor α-β-dual-receptor blockers was associated with PEA or asystole compared with VT/VF (*Figure [3](#euaa124-F3){ref-type="fig"}*). The results for the individual beta-blockers for both registries are listed in the [Supplementary material online, *Table S5*](https://academic.oup.com/europace/article-lookup/doi/10.1093/europace/euaa124#supplementary-data).

![Use of beta-blockers and odds of first-registered heart rhythm being non-shockable. (*A*) DANCAR registry. (*B*) ARREST registry. CI, confidence interval; DHP, dihydropyridine. Numbers in table are number (%) unless indicated otherwise. Error bars denote 95% confidence interval. The results are adjusted for all the covariates listed in *Table [1](#euaa124-T1){ref-type="table"}*.](euaa124f2){#euaa124-F2}

![Use of beta-blockers and odds of PEA vs. VT/VF and asystole vs. VT/VF. (*A*) PEA versus VT/VF. (*B*) Asystole vs. VT/VF, PEA vs. asystole. Data on PEA and asystole only available in ARREST. Numbers in table are number (%) unless indicated otherwise. Error bars denote 95% confidence interval. The results are adjusted for all the covariates listed in *Table [1](#euaa124-T1){ref-type="table"}*. CI, confidence interval; PEA, pulseless electrical activity; VT/VF, ventricular tachycardia/ ventricular fibrillation.](euaa124f3){#euaa124-F3}

When we stratified the analyses according to the dosage, we found that only high dose of any beta-blocker, non-selective, and α-β-dual-receptor blockers were associated with increased likelihood of non-shockable rhythm ([Supplementary material online, *Figure S1*](https://academic.oup.com/europace/article-lookup/doi/10.1093/europace/euaa124#supplementary-data)).

Subgroup analysis---witnessed out-of-hospital cardiac arrest with estimated time to rhythm analysis ≤10 min
-----------------------------------------------------------------------------------------------------------

In both cohorts, the main results were confirmed by subgroup analysis including only witnessed OHCAs (bystander or EMS witnessed) with estimated time to rhythm analysis ≤10 min: use of non-selective beta-blockers was associated with increased odds of non-shockable rhythm \[DANCAR: OR~adj~ 1.94 (1.33--2.83), ARREST: OR~adj~ 6.79 (2.25--20.50)\], while use of β1-selective beta-blockers or α-β-dual-receptor blockers was not ([Supplementary material online, *Figure S2*](https://academic.oup.com/europace/article-lookup/doi/10.1093/europace/euaa124#supplementary-data)).

Subgroup analysis---baseline comorbidity
----------------------------------------

In DANCAR, in subgroup analyses based on the presence of certain comorbidities, use of non-selective beta-blockers was consistently associated with higher odds of non-shockable rhythm compared with no use of any beta-blocker, even among patients without cardiac comorbidity ([Supplementary material online, *Table S6*](https://academic.oup.com/europace/article-lookup/doi/10.1093/europace/euaa124#supplementary-data)). We found a significant association between α-β-blockers and non-shockable heart rhythm only among patients with IHD and in patients without cardiac disease ([Supplementary material online, *Table S6*](https://academic.oup.com/europace/article-lookup/doi/10.1093/europace/euaa124#supplementary-data)). No association in any subgroup was seen for β1-selective blockers. Subgroup analyses for ARREST were not reported because of too small numbers to get meaningful results.

Sensitivity analysis angiotensin-converting enzyme inhibitors in relation to shockable rhythm
---------------------------------------------------------------------------------------------

In both registries, we found no increased odds of non-shockable rhythm upon use of ACE inhibitors ([Supplementary material online, *Figure S3*](https://academic.oup.com/europace/article-lookup/doi/10.1093/europace/euaa124#supplementary-data)).

Discussion
==========

In this observational study using real-world data from two independent population-based OHCA-registries, we found that use of non-selective beta-blockers, but not β1-selective beta-blockers, was associated with non-shockable rhythm. The use of α-β dual receptor blocker was significantly associated with non-shockable rhythm in DANCAR---albeit to a lesser extent than non-selective beta-blockers---and not significantly in ARREST.

Previous studies have investigated the association between use of beta-blockers and first-registered heart rhythm in OHCA patients, but obtained conflicting results.[@euaa124-B6]^,^[@euaa124-B15] In one single-centre study, a five-fold increased likelihood of presenting with PEA in patients treated with beta-blockers was observed.[@euaa124-B6] The authors hypothesized that the attenuation of the compensatory catecholaminergic vasoconstriction in the setting of myocardial dysfunction due to an acute coronary occlusion could result in circulatory collapse and a low blood pressure characteristic of PEA; this effect may be more plausible in case of non-selective drugs with concomitant α-blockade.[@euaa124-B6] However, the small number of cases included in the study (*N* = 179) and the high number of cases excluded due to unknown beta-blocker status (25%) limit the reliability of these results. Conversely, another study with a larger cohort including 8266 OHCAs found that use of beta-blockers was not associated with an increased risk of non-shockable heart rhythm.[@euaa124-B7] The fact that this study only investigated the overall effect of beta-blockers on first-registered heart rhythm without distinguishing among the different classes may explain why those results differed from ours. While we observed an association of non-shockable rhythm with the overall use of beta-blockers in the larger DANCAR registry (but not in the ARREST registry), this association was modest, and mainly driven by non-selective beta-blockers. In neither registry did we find an association of non-shockable rhythm with β1-selective beta-blockers, which represent almost 85% of the prescribed beta-blockers in ARREST.

The classes of beta-blockers differ substantially between each other in several important pharmacodynamic and pharmacokinetic properties, particularly their affinity and selectivity for the distinct adrenoceptors.[@euaa124-B16] Correspondingly, they have distinct clinical indications.[@euaa124-B17] Hence, the observed association of non-selective beta-blockers with non-shockable rhythm may, in addition to their pharmacological effect, be related to the underlying disease for which these drugs are prescribed, e.g. prevention of variceal haemorrhage in patients with liver disease, which is independently related to non-shockable rhythm.[@euaa124-B9] Nonetheless, non-selective beta-blockers remained significantly associated with non-shockable rhythm when comorbidities were taken into account.

Similarly, we found that patients taking β1-selective beta-blockers had a high burden of cardiac diseases such as IHD and CHF or were treated with digoxin or class I and III antiarrhythmic drugs. All these conditions have been related to shockable rhythm, and hence they may have masked the association with non-shockable rhythm.[@euaa124-B9]^,^[@euaa124-B18] Accordingly, we did not observe an association with non-shockable rhythm for sotalol, which is classified as non-selective beta-blocker according to the ATC classification and is used as an antiarrhythmic drug in cardiac patients. Besides, due to our study design, we lacked information about important clinical features, such as left ventricular ejection fraction. Therefore, we cannot exclude that confounding by indication or unmeasured confounders have driven our results. To try to address these issues, we conducted subgroup analyses only including patients with similar baseline characteristics which are known to influence the use of beta-blockers and the first-registered rhythm in OHCA such as IHD and CHF,[@euaa124-B4]^,^[@euaa124-B9]^,^[@euaa124-B18] and in patients without baseline cardiovascular comorbidities. Our main results were confirmed in these subgroup analyses. Thus, we found no evidence that differences in patient profiles accounted for differential effects on first-registered heart rhythm upon use of beta-blockers.

It may be also highlighted that animal studies have demonstrated that pre-arrest therapy with various types of beta-blockers have different effects on the characteristics of the first-registered heart rhythm and the probability of achieving return of spontaneous circulation.[@euaa124-B15]^,^[@euaa124-B19] For instance, some non-selective beta-blockers such as timolol and propranolol were found to have a higher beta-blockade potency and a larger antifibrillatory potency compared with other type of beta-blockers.[@euaa124-B20] Similarly, in the analyses stratified by the dosage, we observed a trend towards increasing odds of non-shockable rhythm with increasing dosage only for non-selective drugs, suggesting a causal relationship.

Whatever the mechanism, it must be emphasized that beta-blockers remain among the very few drugs that reduce the incidence of VT/VF because of their antiarrhythmic and antifibrillatory properties. Thus, use of beta-blockers remains favourable because it is likely to prevent the occurrence of VT/VF and OHCA in the first place in many patients, although patients who still experience OHCA while on beta-blockers are more likely to have non-shockable rhythm.

Considering the importance of the first-registered heart rhythm during resuscitation attempts and its influence on post-resuscitation management,[@euaa124-B10] future studies are required to shed light on the physiological mechanisms which link non-selective beta-blockers to non-shockable rhythm.

Strengths and limitations
-------------------------

A major strength is that DANCAR and ARREST are specifically designed to study the incidence, outcomes and determinants of OHCA, which allows accurate data collection from every OHCA patient. Also, the population-based design minimized selection bias by prospectively including every OHCA, rendering our findings representative for the community at large. The main limitation is inherent to the observational nature of our study, i.e. we could only detect associations, and conclusions on causality should be made with caution. As previously discussed, confounding by indication may have driven our results. Nevertheless, when we repeated the analysis for ACE inhibitors, which have similar indications as beta-blockers and whose users had similar differences in baseline characteristics compared with non-users, we did not find an association with any type of first-registered heart rhythm, rendering it unlikely that residual confounding alone may have driven our results.

In both registries, the time to rhythm analysis by EMS was only an estimate, which may be particularly inaccurate in case of unwitnessed OHCAs. However, restricting the analyses to witnessed OHCAs with estimated time to rhythm analysis ≤10 min did not alter the results.

Another limitation is that data on pre-existing disease were missing in 7.6% of all OHCA patients from ARREST, but the missing data were distributed proportionally between users and non-users of beta-blockers. Furthermore, in both registries, we did not have information about the therapeutic indication for the use of beta-blockers. Lastly, it should be acknowledged that the association between non-selective beta-blockers and PEA was barely significant (lower 95% CI is 1.01) in the ARREST registry.

Conclusions
===========

Non-selective beta-blockers, but not β1-selective beta-blockers, are associated with non-shockable rhythm in OHCA.
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